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Abstract
Background: C-telopeptide fragments of type II collagen (CTX-II) are created during articular cartilage breakdown
and CTX-II is considered useful as a biomarker of osteoarthritis. The primary objective of the present study was to
explore the relationship between urinary CTX-II concentration and patient characteristics, patient-reported outcome,
muscle strength, and rehabilitation in patients with isolated focal knee cartilage lesions. Furthermore, the secondary
objective was to examine differences in urinary CTX-II concentration between patients with focal cartilage lesions
and healthy controls.
Methods: 48 patients (mean age 33.4 years, standard deviation 9.0) with a focal full-thickness (International Cartilage
Repair Society grade 3 or 4) cartilage lesion on the medial or lateral femoral condyle were included. After baseline
assessments, the patients completed a 3-month rehabilitation program and 44 patients attended the 3 month
follow-up. Baseline and follow-up assessments consisted of urinary CTX-II, the Knee Injury and Osteoarthritis Outcome
Score (KOOS), and isokinetic quadriceps and hamstring muscle strength measurements. CTX-II was also analysed
in urine samples from 6 healthy individuals, serving as normal controls. Correlations were classified as very weak
(correlation coefficient [r] < 0.20), weak (r = 0.20 – 0.39), moderate (r = 0.40 – 0.59), strong (r = 0.60 – 0.79), and very
strong (r > 0.80).
Results: Except for age and quadriceps strength, no significant correlations were found between CTX-II concentrations
and baseline characteristics, KOOS, or muscle strength. Except for age, all correlations were considered as weak or very
weak. The patients with a focal cartilage lesion had significantly higher mean CTX-II concentration than the healthy
control individuals both at baseline (p = 0.001) and at follow-up (p = 0.001). The mean CTX-II concentration tended to
decrease during rehabilitation, but the reduction was not significant (p = 0.076).
Conclusions: The current exploratory study demonstrated that patients with a focal cartilage lesion of the knee had
higher concentrations of urinary CTX-II than healthy individuals. In addition, CTX-II concentration tended to decrease
during rehabilitation.
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Background
Focal cartilage lesions of the knee are a common finding
in arthroscopic surgery [1] and may lead to debilitating
knee complaints [2]. Even though focal cartilage lesions
of the knee are considered as a possible risk factor for
later osteoarthritis (OA) [3,4], the natural history of
these lesions is not well understood.
The development of OA is traditionally assessed by plain
radiographs. However, radiographic changes develop over
relatively long periods of time and occur in late stages of
OA. Magnetic resonance imaging (MRI), including tech-
niques such as d’GEMRIC, T2-mapping, and T1-rho, can
also be used to assess both quantitative and qualitative
changes of cartilage [5]. However, these are expensive and
time-consuming methods. A third option in monitoring
OA development is joint tissue-related biomarkers pro-
duced during synthesis or degradation of articular cartilage.
One such biomarker is C-telopeptide fragments of
type II collagen (CTX-II) created during articular cartil-
age breakdown and excreted in urine [6]. Urinary CTX-
II has been shown to be elevated in correlation with the
presence and severity of knee OA [7-9] and to correlate
with joint loading and exercise in patients with knee OA
[10]. In addition, decreasing CTX-II concentrations after
anterior cruciate ligament reconstruction have been as-
sociated with decreasing knee pain and improving func-
tion [11]. Consequently, there might be a potential of
using CTX-II in assessing the development of degenera-
tive changes and treatment effects also in patients with
focal cartilage lesions of the knee. However, most studies
on CTX-II have focused on patients with knee OA and
not on patients with focal cartilage lesions. Knowledge
from studies on knee OA patients can not be directly
transferred to patients with focal cartilage lesions, as they
differ from each other, especially regarding patient age.
If CTX-II is to be used in monitoring treatment effects
and natural history of cartilage lesions, there is a need for
knowledge on the relationship between CTX-II concentra-
tions and various patient-related clinical features and
changes in CTX-II concentrations following rehabilitation
in patients with cartilage lesions. Thus, the purpose of the
present study was to explore these issues in a cohort of
patients with focal knee cartilage lesions undergoing a 3-
month rehabilitation program. The primary objective was
to investigate the relationship between CTX-II concentra-
tions and age, gender, Body Mass Index (BMI), duration
of symptoms, previous ipsilateral knee surgery, size of the
cartilage lesion, knee muscle strength, and patient-
reported outcome measures in patients with focal knee
cartilage lesions. The secondary objectives were to exam-
ine if the patients showed different CTX-II concentrations
than healthy control individuals and to examine changes
in the patients’ CTX-II concentrations following a 3-
month rehabilitation program.
Methods
Patients and procedures
The present study was a part of the Oslo Cartilage Active
Rehabilitation and Education Study (The Oslo CARE
study) on rehabilitation of patients with focal cartilage le-
sions of the knee [12]. The study was a prospective cohort
study, and the inclusion criteria were age between 18 to
50 years, an arthroscopically verified focal cartilage lesion
of International Cartilage Repair Society (ICRS) grade 3 or
4 on the medial or lateral femoral condyle of at least
1.5 cm in diameter and less than 6.0 cm2, and Lysholm
score [13] less than 75. Lesion size was estimated using a
standard 4-mm arthroscopic probe, measuring the longest
anteroposterior distance and the width of the cartilage le-
sion. Exclusion criteria were OA, untreated meniscus le-
sion, major ligament injury, and major malalignment. The
presence of OA was evaluated radiographically [14] ac-
cording to the Kellgren-Lawrence (K-L) classification by
the including orthopedic surgeon, [15] and OA was de-
fined as K-L grade ≥ 2.
Prior to inclusion, all patients signed a written informed-
consent form. The study was conducted in accordance
with the Declaration of Helsinki, approved by The South-
Eastern Norway Regional Ethical Committee and regis-
tered at ClinicalTrials.gov (NCT00885729).
Patients were recruited consecutively from a cartilage
centre at a university hospital and 48 out of 50 eligible
patients were included in the study. All patients went
through a diagnostic arthroscopy prior to inclusion.
Baseline testing was performed at a minimum of 6 weeks
after the diagnostic arthroscopy. All patients (n = 48) com-
pleted a test session which included collection of urine
samples, patient-reported outcome measures, and isokin-
etic muscle strength testing. After the baseline testing, the
patients attended a 3-month active rehabilitation program
consisting of cardiovascular training, knee and hip pro-
gressive resistance training, and neuromuscular training.
The rehabilitation program and its feasibility have been
described by Wondrasch et al. [12], and showed a high ad-
herence rate, clinically meaningful changes of patient-
reported outcomes, positive load progression, and the oc-
currence of very few joint-specific adverse events [12].
After completing the rehabilitation program at a median
of 3.1 months (range, 2.8-8.7), 44 patients attended a
follow-up test session and conducted the same assess-
ments as the baseline testing. 4 patients did not attend the
3-month follow-up and were considered lost to follow-up.
Variables
Baseline characteristics
Of the 48 patients included, 34 were male. Mean age
was 33.4 years (standard deviation [SD], 9.0) and mean
Body Mass Index (BMI) 27.3 (SD, 4.9). Median duration
of symptoms was 27 months (range, 2-240), 24 patients
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related their debut of symptoms to a knee trauma and
13 patients had a history of osteochondritis dissecans.
Median number of previous ipsilateral knee surgeries
was 2 (range, 0-4). In 37 cases the cartilage lesion was
located on the medial femoral condyle, and in the 11
remaining cases the lesion was located on the lateral
femoral condyle. The mean size of the cartilage lesion
was 2.9 cm2 (SD, 1.3). There were no differences in base-
line characteristics between the patients lost to follow-
up (n = 4) and the rest of the patients (n = 44) (data not
shown).
CTX-II
Urine samples were collected during daytime just prior
to the physical testing, and stored at -70°C until ana-
lysis. CTX-II concentrations were determined using an
enzyme immunoassay (EIA) kit based on a mouse
monoclonal antibody against the EKGPDP sequence of
human type II collagen C-telopeptide (Urine Carti-
Laps® EIA; Nordic Bioscience, Herlev, Denmark). Urine
samples were diluted as needed, ranging from 1:1 to
1:50. CTX-II concentrations were corrected for urinary
creatinine concentration as recommended by the
producer, using the formula (corrected CTX−II concen-
tration [ng/mmol] = 1000 × urine CartiLaps [μg/L]/
creatinine [mmol/L]).
Knee Injury and Osteoarthritis Outcome Score (KOOS)
KOOS is a self-administered knee-specific questionnaire,
validated for patients with several types of knee injury,
knee OA, and for patients with cartilage lesions [16-18].
KOOS consists of 42 questions distributed in 5 subscales:
Pain (9 questions), Symptoms (7 questions), Activities in
Daily Living (ADL) (17 questions), Function in Sport and
Recreation (Sport/Rec) (5 questions) and Knee-Related
Quality of Life (QoL) (4 questions). Each subscale is
scored individually on a scale ranging from 0 (worst) to
100 (best) [19].
The results from the KOOS reported by the current
patient cohort at baseline and at follow-up after
3 month rehabilitation have previously been published
by Wondrasch et al. [12], and are referred to here as de-
scriptives. The mean KOOS values at baseline (n = 48)
were: Pain 54.8 (SD, 17.7), Symptoms 59.0 (SD, 17.0),
ADL 70.1 (SD, 17.6), Sport/rec 27.5 (SD, 20.6), and QoL
27.6 (SD, 16.5). At follow-up (n = 44) after 3-month re-
habilitation, the mean KOOS values were: Pain 60.1 (SD,
17.8), Symptoms 64.9 (SD, 15.9), ADL 75.6 (SD, 17.0),
Sport/rec 41.0 (SD, 25.4), and QoL 39.4 (SD, 20.6).
Isokinetic muscle strength
Isokinetic muscle strength testing for the quadriceps and
the hamstrings were performed with an isokinetic dyna-
mometer (Biodex 6000; Biodex Medical Systems, Inc,
Shirley, NY). Prior to testing, the patients performed a
10-minute warm-up on a stationary bike. The test was
conducted using 5 repetitions at an angular velocity of
60°/s and muscle strength was quantified based on peak
torque (Nm).
The results from the isokinetic quadriceps and ham-
strings muscle strength measurements of the current
study cohort at baseline and at follow-up after
3 month rehabilitation have previously been published
by Wondrasch et al. [12], and are referred to here as
descriptives. The mean quadriceps strength of the in-
jured leg at baseline (n = 48) was 139.7 Nm (SD 63.9),
and at follow-up (n = 44) after 3 months 178.2 Nm
(SD 59.6). At baseline, this represented a mean of
74.2% (SD, 27.2) of the quadriceps strength of the un-
injured limb, and at follow-up 88.4% (SD, 18.1). The mean
hamstrings strength of the injured leg at baseline (n = 48)
was 77.9 Nm (SD, 38.6), and at follow-up (n = 44)
97.4 Nm (SD, 28.9). At baseline, this represented a mean
of 84.1% (SD, 36.5) of the hamstrings strength of the unin-
jured limb, and at follow-up 93.0% (SD, 15.8).
Controls
For CTX-II analysis, urine samples were collected from
6 healthy individuals with no record of knee problems
or major knee injury. These were 5 males and 1 female,
mean age 35.7 years (SD, 2.3). The urine samples from
these individuals were collected at one time point only,
as they did not attend the rehabilitation program, and
served as normal controls for both the baseline and
follow-up patient CTX-II concentrations.
Statistical analysis
All analyses were performed using Statistical Package of
Social Sciences (SPSS) software version 20 (SPSS, Inc, an
IBM Company, Chicago, Illinois, US). All CTX-II con-
centrations were log transformed to reduce the effect of
outliers. For correlations between CTX-II and baseline
variables and outcome measures, Pearson correlation
coefficients were calculated. Correlations were classi-
fied as very weak (correlation coefficient [r] < 0.20),
weak (r = 0.20 – 0.39), moderate (r = 0.40 – 0.59), strong
(r = 0.60 – 0.79), and very strong (r > 0.80). The Mann-
Whitney U test was used to compare the mean CTX-II
concentrations between patients and controls. Paired
samples t-test was used to compare the mean CTX-II
concentrations pre and post rehabilitation. The level of
significance was defined as p ≤ 0.05.
Results
CTX-II
At baseline (n = 48) the mean CTX-II concentration of
the patients with a focal cartilage lesion of the knee was
579 ng/mmol (95% CI, 266 to 891) (log 2.52 [95% CI,
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2.41 to 2.63]). At follow-up (n = 44) after 3-month re-
habilitation period there was a decrease to 514 ng/mmol
(95% CI, 278 to 750) (log 2.50 [95% CI, 2.38 to 2.61]).
The difference in mean CTX-II concentration from
baseline to follow-up (n = 44), -102 (95% CI, -236 to 33)
(log –0.05 [95% CI, -0.11 to 0.01]), was not statistically
significant (p = 0.076).
The healthy control individuals (n = 6) had a mean
CTX-II concentration of 129 ng/mmol (95% CI, 111.2 to
146.8) (log 2.11 [95% CI, 2.04 to 2.17]). The patients
with a focal cartilage lesion showed a significantly higher
mean concentration of CTX-II than the healthy control
individuals both at baseline (p = 0.001) and at follow-up
(p = 0.001).
CTX-II and baseline characteristics
Correlations analysis between the baseline characteristics
(age, gender, BMI, duration of symptoms, previous knee
surgery, and size of cartilage lesion) and CTX-II at base-
line, follow-up, and change from baseline to follow-up re-
vealed no significant correlations except for age (Table 1).
Except for age, all correlations were considered as weak or
very weak.
CTX-II and KOOS
Correlation analysis between KOOS at baseline and CTX-
II at baseline, between KOOS at follow-up and CTX-II at
follow-up, and between change in KOOS from baseline to
follow-up and change in CTX-II from baseline to follow-
up revealed no significant correlations (Table 2). All corre-
lations were considered as weak or very weak.
CTX-II and muscle strength
Correlation analysis between isokinetic muscle strength
at baseline and CTX-II at baseline, between isokinetic
muscle strength at follow-up and CTX-II at follow-up,
and between change in isokinetic muscle strength from
baseline to follow-up and change in CTX-II from base-
line to follow-up revealed no significant correlations ex-
cept for quadriceps strength at baseline (Table 3). All
correlations were considered as weak or very weak.
Discussion
The present study demonstrated that patients with focal
cartilage lesions of the knee had higher CTX-II concen-
trations compared with healthy individuals. In addition,
there was a trend toward a reduction in CTX-II concen-
tration among patients with focal knee cartilage lesions
after completing a 3 month rehabilitation program. Fur-
thermore, the present study revealed, except for age, no
clinically relevant relationships between CTX-II concen-
trations and a variety of clinical features in patients with
focal knee cartilage lesions. These findings add new in-
formation, as the present study, to our knowledge is the
first to investigate urinary CTX-II concentrations among
patients with isolated focal knee cartilage lesions. Previ-
ous studies on CTX-II and knee problems have primarily
focused on patients with knee OA [7-10,20-22], in
addition to one study on patients with anterior cruciate
ligament reconstruction [11].
It has previously been shown in a study of 650 healthy
individuals with age between 20 to 87 years that CTX-II
concentrations vary considerably with age [23]. In line
with this study, the present study revealed a significant
and moderate to strong correlation between age and
CTX-II concentrations, also in this relatively young pa-
tient population with focal cartilage lesions.
A previous study by Ding et al. [20] showed that knee
cartilage lesion severity was significantly associated with
CTX-II concentration, which is in contrast to the
present study, where no correlation between cartilage le-
sion size and CTX-II concentration was found. However,
these findings are difficult to compare, as the cohort of
patients in the two studies were different. The patients
in the study by Ding et al. were older (mean age
45 years), they had radiographic OA, and the cartilage
lesions were classified by MRI, while the patients in the
present study were younger (mean age 33 years), they
had no radiographic OA, and the cartilage lesions were
classified arthroscopically.
Even though a statistically significant correlation be-
tween CTX-II and quadriceps strength was found in the
present study, the correlation was classified as weak and
Table 1 Correlations between baseline characteristics and CTX-IIa at baseline, at follow-up and change from baseline to
follow-up
CTX-II at baseline CTX-II at follow-up ΔbCTX-II
Baseline characteristic n rc pd n rc pd n rc pd
Age 48 -0.566 0.001 44 -0.694 <0.001 44 -0.199 ns
Gender 48 0.205 ns 44 0.187 ns 44 -0.069 ns
Body Mass Index 48 -0.247 ns 44 -0.151 ns 44 0.201 ns
Duration of symptoms 48 -0.088 ns 44 -0.086 ns 44 0.016 ns
Previous knee surgery 48 0.060 ns 44 -0.018 ns 44 0.005 ns
Size of cartilage lesion 46 0.100 ns 43 0.065 ns 43 -0.137 ns
aLog transformed values; bΔ, change from baseline to follow-up; cr, Pearson correlation coefficient; dp, level of significance; ns, not significant.
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therefore not considered clinically relevant. Hence, ex-
cept for age, no clinically relevant relationships between
CTX-II and the clinical features studied (gender, BMI,
duration of symptoms, previous knee surgery, patient-
reported outcome, and muscle strength) were found in
the present study. Based on these results, the value of
using CTX-II on an individual basis to characterize pa-
tients with focal knee cartilage lesions will be limited.
The mean CTX-II concentration found among the pa-
tients in the present study were 579 ng/mmol, which is
on a similar or even a higher level than CTX-II concen-
trations found in previous studies on patients with OA.
Sowers et al. [7] found a mean CTX-II concentration of
345 ng/mmol in 20 patients with severe knee OA (K-L
grade 3-4), and Jung et al. [24] reported a mean concen-
tration of 429 ng/mmol in 37 patients with knee OA.
Furthermore, in the present study the CTX-II concentra-
tions among the patients with focal cartilage lesions
were elevated compared to the healthy individuals. This
elevation is an indication of an increased level of cartil-
age degradation. Even though patients with radiographic
or arthroscopically diagnosed OA were excluded from
the present study, the CTX-II concentrations were raised
compared to the healthy individuals. Whether this raise
originates from cartilage degradation directly in the car-
tilage lesion, from its nearby surroundings, and/or from
a more generalized degradation process in the knee, like
pre-radiographic OA, is not possible to differentiate in
this study. Moreover, the possibility of leakage of newly
synthesized collagen from the lesion area can not be
ruled out. However, since the present study proposes
that focal cartilage lesions affect CTX-II concentration,
there might be a potential of using CTX-II in the evalu-
ation of the natural history of such lesions.
In the present study there was a trend toward a reduc-
tion in CTX-II concentration among patients with focal
knee cartilage lesions after completing a 3-month re-
habilitation program. This trend could be related to a
spontaneous healing of the lesion or just due to varia-
tions over time, however, it could also indicate a possible
positive effect of rehabilitation on cartilage. The latter is
supported by a previous study on cartilage biomarkers
and effects of exercise in patients with knee OA, which
suggested a potential beneficial role of exercise on cartil-
age structure [10].
The strengths of the present study were the prospect-
ive design and the low rate of patients lost to follow-up,
combined with a high adherence rate to the rehabilita-
tion program [12].
On the other hand, the present study has several limi-
tations. The patients were recruited from a cartilage
centre and may not be representative of a broad popula-
tion of patients with focal cartilage lesions of the knee
[25]. There was no randomization or actual control
group. Even though CTX-II concentrations were mea-
sured in 6 healthy individuals acting as controls, this
group was small and only matched for age. Among the
controls, CTX-II concentrations were measured at only
Table 2 Correlations between CTX-IIa and Knee Injury and Osteoarthritis Outcome Score (KOOS) at baseline, follow-up
and change from baseline to follow-up
Baseline CTX-II vs. baseline KOOS (n = 48) Follow-up CTX-II vs. follow-up KOOS (n = 44) ΔbCTX-II vs. ΔbKOOS (n = 44)
rc pd rc pd rc pd
KOOS Pain -0.093 ns 0.091 ns 0.078 ns
KOOS Symptoms -0.140 ns 0.082 ns 0.251 ns
KOOS ADLe -0.190 ns 0.124 ns 0.058 ns
KOOS Sport/Rec -0.161 ns 0.199 ns -0.077 ns
KOOS QoLf -0.088 ns 0.060 ns -0.114 ns
aLog transformed values; bΔ, change from baseline to follow-up; cr, Pearson correlation coefficient; dp, level of significance; ns, not significant; eADL, Activity of
Daily Living; fQoL, Quality of Life.
Table 3 Correlations between CTX-IIa and isokinetic muscle strength (IMS) at baseline, follow-up and change from
baseline to follow-up
Baseline CTX-II vs. baseline IMS (n = 48) Follow-up CTX-II vs. follow-up IMS (n = 44) ΔbCTX-II vs. ΔbIMS (n = 44)
rc pd rc pd rc pd
Quadriceps, injured limb -0.297 0.040 -0.081 ns -0.054 ns
Quadriceps, %e -0.299 0.039 0.069 ns -0.012 ns
Hamstrings, injured limb -0.176 ns -0.045 ns 0.150 ns
Hamstrings, %e -0.148 ns -0.003 ns 0.069 ns
aLog transformed values; bΔ, change from baseline to follow-up; cr, Pearson correlation coefficient; dp, level of significance; e%, isokinetic muscle strength injured
limb in percentage of isokinetic muscle strength uninjured limb; ns, not significant.
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one time point, and they did not attend the rehabilita-
tion program, perform any of the muscle strength testing
or answer the KOOS questionnaire. Additionally, since
the power analysis was done for another part of the
study [12], a priori power calculation was not based on
CTX-II as the outcome measure of interest. This is a
major limitation, and considering the skewness in the
confidence interval for the difference between mean
CTX-II concentrations at baseline and follow-up, the
present study might be underpowered. For further stud-
ies on CTX-II and treatment effects in patients with
focal cartilage lesions we recommend that the findings
from the present exploratory study are taken into ac-
count when calculating sample size.
Due to the limitations of the present exploratory study,
further and improved studies on CTX-II in patients with
focal cartilage lesions are needed before it can be de-
cided whether urinary CTX-II concentration can be used
in the evaluation of treatment effects and natural history
of these lesions.
Conclusions
The present exploratory study showed that patients with
focal cartilage lesions of the knee had higher concentra-
tions of CTX-II than healthy individuals. Although sta-
tistically not significant, CTX-II concentrations tended
to decrease during rehabilitation of these patients. More-
over, except for age, no clinically relevant relationships
between CTX-II and a variety of clinical features in pa-
tients with focal knee cartilage lesions were observed.
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